Brain PET Scan for Dementia, Tumors, and Epilepsy: Complete Guide

Brain PET imaging covers three clinical worlds that share little except the technology: distinguishing dementia subtypes, evaluating brain tumors after treatment, and localizing the focus of drug-resistant epilepsy. Each uses different tracers, different protocols, and different referral pathways. This article explains what brain PET shows in each scenario and where to get the right scan if your local options are limited.

When Brain PET Is Ordered (Beyond Cancer)

Standard indications:

• Suspected Alzheimer's disease when clinical picture or MRI is ambiguous
• Differential diagnosis of dementia subtypes (Alzheimer's vs frontotemporal vs Lewy body)
• Brain tumor recurrence vs radiation necrosis after surgery and radiation
• Drug-resistant focal epilepsy prior to consideration of resective surgery
• Atypical parkinsonism evaluation (Parkinson's vs MSA vs PSP)
• Encephalitis or unexplained subacute cognitive decline

Most brain PET in routine clinical practice uses FDG. Specialized tracers (amyloid, tau, FET, DAT) address specific questions that FDG cannot answer.

Alzheimer's vs Frontotemporal vs Lewy Body Patterns

FDG PET shows characteristic regional hypometabolism (areas of reduced glucose use) in each dementia subtype:

Dementia	Hypometabolic pattern
Alzheimer's disease	Bilateral temporoparietal, posterior cingulate, precuneus
Frontotemporal dementia (behavioral)	Bilateral frontal lobes, anterior temporal
Frontotemporal dementia (primary progressive aphasia)	Left frontotemporal asymmetric
Lewy body dementia	Bilateral occipital + temporoparietal
Vascular dementia	Patchy, follows vascular territories
Normal aging	Mild bifrontal, otherwise preserved

These patterns are recognized by trained neuroradiologists in 70–85% of cases. When the pattern is ambiguous, more specific tracers (amyloid PET for Alzheimer's, tau PET for confirmation, DAT for Lewy body) provide additional confidence.

Tumor Recurrence vs Radiation Necrosis

After treatment of high-grade glioma (glioblastoma, anaplastic astrocytoma), follow-up MRI often shows new contrast enhancement. The clinical question: is this recurrent tumor (requiring repeat surgery or systemic treatment) or radiation necrosis (a treatment-related side effect that improves with steroids)?

MRI alone struggles to distinguish them. Several PET tracers help:

• FDG PET: tumor recurrence often shows FDG uptake higher than surrounding normal cortex; radiation necrosis shows uptake lower than cortex. Sensitivity 60–80%.
• F-18 FET (Fluoroethyltyrosine): an amino acid tracer; tumor cells take up FET avidly, necrosis does not. Sensitivity 85–95%. Widely used in Europe.
• C-11 methionine: similar concept to FET; older but well-validated.
• F-18 DOPA: amino acid analog; used in low-grade gliomas.

Top Chinese centers carry FET. PUMC Beijing, Huashan Hospital Shanghai, and Tiantan Hospital Beijing (the leading neurosurgical center in China) all offer FET PET.

Epilepsy Focus Localization (Interictal vs Ictal)

For drug-resistant focal epilepsy in patients considered for resective surgery, FDG PET helps localize the seizure focus:

• Interictal FDG PET (between seizures): the focus shows reduced glucose uptake (hypometabolism). Sensitivity 70–80% for temporal lobe epilepsy.
• Ictal SPECT (during seizure): the focus shows increased blood flow. Requires a specialized inpatient monitoring unit.
• PET-MRI fusion: increasingly used to overlay FDG findings on detailed structural MRI.

The hypometabolic area on interictal FDG often extends beyond the actual seizure focus — a phenomenon called "remote effect." Surgical planning combines PET findings with video-EEG monitoring and high-resolution MRI.

Parkinsonian Syndromes with DAT and FDG

For movement disorders, two PET (or SPECT) tracers separate Parkinsonian syndromes:

• DAT (dopamine transporter) imaging — often done as SPECT with I-123 ioflupane (DaTscan). Shows presynaptic dopaminergic deficit in Parkinson's disease, MSA, PSP, and dementia with Lewy bodies. Distinguishes these from essential tremor (DAT normal) and drug-induced parkinsonism (DAT normal).
• FDG PET patterns then distinguish Parkinson's from atypical parkinsonisms:

Diagnosis	FDG pattern
Parkinson's disease	Hypermetabolic putamen + thalamus, hypometabolic parietal/occipital cortex
Multiple system atrophy (MSA)	Hypometabolic putamen, cerebellum
Progressive supranuclear palsy (PSP)	Hypometabolic midbrain, frontal cortex
Corticobasal syndrome	Asymmetric cortical hypometabolism

For dementia or movement disorder workup needing specialized tracers, our team can help.

Tracer Choice: FDG, Amyloid, Tau, FET

A practical decision tree for brain PET tracer choice:

1. Dementia workup, MRI inconclusive → FDG first; consider amyloid PET if Alzheimer's specifically suspected
2. Amyloid PET positive but unsure if Alzheimer's pathology is active → tau PET (flortaucipir) confirms tau tangles
3. Brain tumor follow-up after radiation → FET (preferred in Europe/China) or FDG
4. Drug-resistant focal epilepsy pre-surgery → interictal FDG; PET-MRI fusion ideal
5. Atypical parkinsonism vs Parkinson's → DAT-SPECT first; FDG adds specificity

The right tracer depends on the specific question. A general "brain PET" order without specifying tracer often defaults to FDG; if your clinical question requires another tracer, ask explicitly.

Cost and Insurance Coverage Globally

Scan	US (cash)	UK (private)	Mainland China
FDG brain PET	$3,000–5,000	£1,500–2,500	¥5,000–8,000
Amyloid PET	$5,000–7,500	£3,000–4,500	¥8,000–12,000
Tau PET	$4,500–6,500	£3,000–4,500	¥9,000–14,000
FET PET (brain tumor)	$4,500–6,000	£2,500–3,500	¥8,000–12,000
DAT-SPECT	$2,500–4,000	£1,200–1,800	¥3,000–5,000

US Medicare now covers amyloid PET when ordered as part of an Alzheimer's diagnostic workup (CMS expanded coverage 2023). Other tracers vary by indication.

Pathway for International Brain PET in China

The Chinese centers with full-spectrum brain PET programs:

• Huashan Hospital (Fudan), Shanghai — leading neurology referral center; amyloid, tau, DAT all available
• Tiantan Hospital, Beijing — top neurosurgical center; FET PET for brain tumors; epilepsy program
• Xuanwu Hospital, Beijing — dementia and movement disorder specialty
• West China Hospital, Chengdu — comprehensive brain PET
• Sun Yat-sen Memorial, Guangzhou — neurology and PET program

International patients typically follow this pathway:

1. Send prior MRI, EEG, neuropsychological testing
2. Pre-arrival video consultation with neurology
3. Arrival day 1: in-person neurology consultation
4. Day 2: brain MRI (if not already current) and pre-PET assessment
5. Day 3: PET scan
6. Day 4: results and treatment discussion

Total stay: 4–7 days depending on tracer availability and follow-up testing.

Frequently Asked Questions

My MRI was negative but my doctor wants amyloid PET. Why?
MRI shows brain structure; amyloid PET shows the protein deposits characteristic of Alzheimer's pathology. The two are complementary. Early Alzheimer's can have normal MRI but positive amyloid PET — and treatment decisions (e.g., starting anti-amyloid drugs like lecanemab) may depend on confirming amyloid status.

Can amyloid PET diagnose Alzheimer's by itself?
No. Amyloid plaques can be present in cognitively normal elderly (15–30% by age 75). A positive scan, combined with clinical symptoms, supports the diagnosis. A negative scan effectively rules out Alzheimer's as the primary cause.

Is FET PET available in the US?
FET PET is limited in the US (academic centers under research protocols). It is more widely available in Europe and increasingly in China. For brain tumor surveillance, this is sometimes a reason for medical travel.

How long does brain PET take?
The scan itself is 15–25 minutes. Total time at the imaging center, including IV setup, tracer injection, uptake period, and the scan, is typically 90–120 minutes.

Can a person with dementia tolerate the scan?
Generally yes. A family member can often stay with the patient through prep. Some sedation is occasionally used for patients with severe agitation, though it can interfere with FDG uptake patterns and should be discussed with the nuclear medicine team.

Are these tracers being used for younger patients?
Increasingly yes, particularly for early-onset cognitive symptoms (under 60), familial Alzheimer's, and post-treatment brain tumor surveillance in younger adults.

Need Help Booking?

SinoCareLink can pre-book brain PET (FDG, amyloid, tau, FET, DAT) at a top Chinese neurological center, coordinate neurology consultation, translate reports into English, and arrange airport pickup. Contact us for a free consultation.